References

Matthews KA et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009;54(25):2366-2373. Link ↗

El Khoudary SR et al. Progression rates of carotid intima-media thickness and adventitial diameter during the menopausal transition. Menopause. 2013. Link ↗

El Khoudary SR et al. Trajectories of estradiol and FSH over the menopause transition and early markers of atherosclerosis after menopause. Eur J Prev Cardiol. 2015;23(7):694-703. Link ↗

Thurston RC et al. Hot flashes and subclinical cardiovascular disease: findings from SWAN Heart. Circulation. 2008;118(12):1234-1240. Link ↗

Thurston RC et al. Menopausal hot flashes and carotid intima media thickness among midlife women. Stroke. 2016;47(12):2910-2915. Link ↗

Thurston RC et al. Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN. J Am Heart Assoc. 2021;10(3):e017416. Link ↗

Nayak A et al. Cardiovascular health characterization using Life's Essential 8 in perimenopausal women: NHANES. J Am Heart Assoc. 2026;15:e046898. Link ↗

Rossouw JE et al. Menopausal hormone therapy and cardiovascular diseases in women with vasomotor symptoms: secondary analysis of the WHI randomized clinical trials. JAMA Intern Med. 2025;185(11):1330-1339. Link ↗

Wang Z et al. Menopausal hormone therapy and cardiovascular risk in women with vasomotor symptoms: target trial emulation. JAMA Intern Med. 2026. Link ↗

Randolph JF Jr et al. Change in FSH and estradiol across the menopausal transition. J Clin Endocrinol Metab. 2011;96(3):746-754. Link ↗

Harlow SD et al. Executive summary of the Stages of Reproductive Aging Workshop + 10. Menopause. 2012;19(4):387-395. Link ↗

Tepper PG et al. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause. 2016. Link ↗

AHA, ACOG, AAP and SMFM. Multisociety framework for cardiovascular health across female life stages. Circulation. October 26, 2026. Link ↗

National Academies of Sciences, Engineering, and Medicine. A New Vision for Women's Health Research. 2024. Link ↗

NIH RCDC funding categories, FY2024, as reproduced by the American Society for Reproductive Medicine. Link ↗

McKinsey Health Institute. Blueprint to close the women's health gap. Link ↗

Cleveland Clinic Consult QD. A new family of NK3 receptor antagonists offer menopausal symptom relief. 2023. Link ↗